CITR CitroTech (CITR) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Chemicals & allied products · CIK 0000894556
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
19
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · no price filed
What the filings say about CITR
Insiders, 180 days
-$325.0K net sold
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan
CitroTech insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, CitroTech Inc. insiders sold a net $325.0K of stock across 705 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 5.6% of the 3,557,467 shares held after it.
- No other insider bought within 30 days.
- 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HUFF CRAIG A bought about $500.0K of CITR on Oct 22, 2026, the largest insider purchase at the company on our record; 19 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 13.3% of the 2,060,557 shares held after it.
- No other insider sold within 30 days.
- 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Conboy Stephen sold about $825.0K of CITR on Aug 4, 2026, the largest insider sale at the company on our record; 19 funds added in the latest 13F quarter.Context
- 700 earlier Form 4 trades (code P or S) here by this insider (595 buys, 105 sales), the last on Mar 19, 2025.
- +0.0% median (+0.0% mean) 90-day return after 30 previous buys.
- The trade is 0.0% of the 390,570 shares held after it.
- No other insider bought within 30 days.
- 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Ralston Theodore bought about $372 of CITR on Mar 20, 2025; 19 funds added in the latest 13F quarter.Context
- 700 earlier Form 4 trades (code P or S) here by this insider (595 buys, 105 sales), the last on Mar 19, 2025.
- +0.0% median (+0.0% mean) 90-day return after 30 previous buys.
- The trade is 0.0% of the 390,603 shares held after it.
- No other insider bought within 30 days.
- 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Ralston Theodore bought about $244 of CITR on Mar 20, 2025; 19 funds added in the latest 13F quarter.Context
- 697 earlier Form 4 trades (code P or S) here by this insider (592 buys, 105 sales), the last on Mar 18, 2025.
- +0.0% median (+0.0% mean) 90-day return after 30 previous buys.
- The trade is 0.0% of the 390,520 shares held after it.
- No other insider bought within 30 days.
- 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Ralston Theodore bought about $238 of CITR on Mar 19, 2025; 19 funds added in the latest 13F quarter.705 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$325.0K over 180 days
-$325.0K over 90 days · +$500.0K of it by a 10%+ holder
below 52% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
19 funds bought in last quarter
below 70% of Pharma & Biotech
Revenue
+194.6% year over year
more than 89% of Pharma & Biotech
Margin
-1546.9% net margin
below 90% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
1.5% of the float short (float per yahoo 2026-10-26) · 2.9 days to cover · settled 2026-09-30
below 75% of Pharma & Biotech
What changed in the last 30 days
Oct 26Director HUFF CRAIG A bought $500.0K (Oct 22)
Watch CITR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-66.2%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CITR: institutional holders (13F)
13F holdings, latest reported quarter
486,620 sh
$2.7M
235,281 sh
$1.3M
176,239 sh
$973.3K
750,000 sh
$750.0K
101,275 sh
$559.0K
Congress trades in CITR
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CITR planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CITR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$99.4K position · as of 2026-06-30
0.1%
VANGUARD EXTENDED MARKET INDEX FUND
$1.1M position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$435.0K position · as of 2026-05-31
0.0%
Victory Extended Market Index Fund
$7.3K position · as of 2026-07-31
0.0%
Fidelity Total Market Index Fund
$228.8K position · as of 2026-05-31
0.0%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND
$44.9K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $325.0K sold by insiders over 180 days, 19 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CITR financials
Revenue growth
+194.6%
XBRL, annual
Net margin
-1546.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Revenue, TTM CITR
| FY Dec 2025 | n/a |
| FY Dec 2024 | $808.4K |
| FY Dec 2023 | $520.6K |
| FY Dec 2022 | n/a |
| FY Dec 2021 | $0 |
| Jun 2026 | $280.7K |
| Mar 2026 | $344.9K |
| Dec 2025 | $436.2K |
| Sep 2025 | $288.2K |
| Jun 2025 | $687.6K |
| Mar 2025 | $1.0M |
| Dec 2024 | $69.6K |
| Sep 2024 | $107.0K |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM CITR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -1,390% |
| Mar 2026 | -1,801% |
| Dec 2025 | -1,399% |
| Sep 2025 | -2,751% |
| Jun 2025 | -1,731% |
| Mar 2025 | -1,090% |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$7.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CITR
| FY Dec 2025 | -$6.1M |
| FY Dec 2024 | -$1.9M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -$1.8M |
| Mar 2026 | -$2.1M |
| Dec 2025 | -$2.5M |
| Sep 2025 | -$1.5M |
| Jun 2025 | -$1.4M |
| Mar 2025 | -$740.9K |
| Dec 2024 | -$617.8K |
| Sep 2024 | -$551.3K |
At each fiscal year end
Single quarter
Debt to equity
0.02x
long-term 2025-09-30 (9 months older than the period end) plus current 2025-09-30 (9 months older than the period end); equity 2026-06-30
Debt to equity CITR
| FY Dec 2025 | 0.02x |
| FY Dec 2024 | 0.03x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.02x |
| Mar 2026 | 0.02x |
| Dec 2025 | 0.02x |
| Sep 2025 | 0.02x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.03x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-45.07x
TTM operating cash flow over long-term 2025-09-30 (9 months older than the period end) plus current 2025-09-30 (9 months older than the period end)
Cash flow to debt CITR
| FY Dec 2025 | -33.97x |
| FY Dec 2024 | -20.01x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -45.07x |
| Mar 2026 | -41.76x |
| Dec 2025 | -33.97x |
| Sep 2025 | -23.18x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -20.01x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-431.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CITR
| FY Dec 2025 | -505.4% |
| FY Dec 2024 | -198.0% |
| FY Dec 2023 | -289.3% |
| FY Dec 2022 | -176.5% |
| FY Dec 2021 | n/a |
| Jun 2026 | -431.0% |
| Mar 2026 | -503.2% |
| Dec 2025 | -505.4% |
| Sep 2025 | -573.7% |
| Jun 2025 | -934.4% |
| Mar 2025 | -363.2% |
| Dec 2024 | -198.0% |
| Sep 2024 | -171.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-257.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CITR
| FY Dec 2025 | -374.7% |
| FY Dec 2024 | -127.7% |
| FY Dec 2023 | -208.0% |
| FY Dec 2022 | -122.7% |
| FY Dec 2021 | -57.5% |
| Jun 2026 | -257.9% |
| Mar 2026 | -301.9% |
| Dec 2025 | -374.7% |
| Sep 2025 | -378.1% |
| Jun 2025 | -359.8% |
| Mar 2025 | -199.4% |
| Dec 2024 | -127.7% |
| Sep 2024 | -102.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital CITR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-287.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CITR
| FY Dec 2025 | -215.2% |
| FY Dec 2024 | -151.5% |
| FY Dec 2023 | -287.1% |
| FY Dec 2022 | -177.1% |
| FY Dec 2021 | n/a |
| Jun 2026 | -287.4% |
| Mar 2026 | -259.4% |
| Dec 2025 | -215.2% |
| Sep 2025 | -196.5% |
| Jun 2025 | -269.7% |
| Mar 2025 | -155.4% |
| Dec 2024 | -151.5% |
| Sep 2024 | -133.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CITR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$57.4M
market value at close 2026-10-23 on 2026-08-07 shares, plus long-term 2025-09-30 (9 months older than the period end) plus current 2025-09-30 (9 months older than the period end), minus cash 2026-06-30
Enterprise value CITR
| FY Dec 2025 | $135.7M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $121.1M |
| Mar 2026 | $161.2M |
| Dec 2025 | $135.7M |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-13.1%
TTM free cash flow over market value at close 2026-10-23
FCF yield CITR
| FY Dec 2025 | -4.3% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -6.3% |
| Mar 2026 | -4.5% |
| Dec 2025 | -4.3% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CITR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.4M | $808.4K | $520.6K | $62.7K |
| Gross profit | n/a | n/a | $387.1K | $60.8K |
| Operating income | -$16.5M | -$5.3M | -$10.1M | -$2.9M |
| Net income | -$36.8M | -$6.9M | -$10.1M | -$2.9M |
| EPS (diluted) | -2.96 | -0.82 | -0.10 | 0.00 |
| Operating cash flow | -$5.9M | -$1.9M | -$1.2M | -$708.5K |
| Cash | $6.3M | $775.1K | n/a | n/a |
| Long-term debt | n/a | $0 | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-27
CITR Stock Sonar score 6/7 axes
Find similar shapesCompareCITR ranks highest on growth (89th percentile) and risk and compliance (77th), and lowest on profitability (8th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CITR filings, in plain words
Are CitroTech insiders buying or selling CITR?
In the 180 days to 2026-10-27, CitroTech insiders were net sellers, a net $325.0K: $500.0K of purchases and $825.0K of sales reported on Form 4, by 1 buyer and 1 seller.
Read the full summary
In the 180 days to 2026-10-27, CitroTech insiders were net sellers of CITR, a net $325.0K across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Most of that figure, $500.0K, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
